Cartesian Therapeutics, Inc.
RNAC
$8.84
$0.121.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 78.00K | 947.00K | 452.00K | 298.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 78.00K | 947.00K | 452.00K | 298.00K |
| Cost of Revenue | 20.43M | 19.46M | 14.69M | 13.80M | 14.87M |
| Gross Profit | -20.43M | -19.39M | -13.74M | -13.35M | -14.57M |
| SG&A Expenses | 8.72M | 7.11M | 8.20M | 7.72M | 7.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.16M | 26.58M | 22.89M | 21.52M | 22.11M |
| Operating Income | -29.16M | -26.50M | -21.94M | -21.07M | -21.81M |
| Income Before Tax | 15.77M | -39.18M | -101.77M | -35.90M | 15.89M |
| Income Tax Expenses | -- | -- | -9.19M | -- | -- |
| Earnings from Continuing Operations | 15.77M | -39.18M | -92.58M | -35.90M | 15.89M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.77M | -39.18M | -92.58M | -35.90M | 15.89M |
| EBIT | -29.16M | -26.50M | -21.94M | -21.07M | -21.81M |
| EBITDA | -28.38M | -25.88M | -21.33M | -20.46M | -21.22M |
| EPS Basic | 0.47 | -1.38 | -3.56 | -1.38 | 0.51 |
| Normalized Basic EPS | -0.71 | -0.59 | -0.48 | -0.46 | -0.47 |
| EPS Diluted | 0.46 | -1.38 | -3.56 | -1.38 | 0.50 |
| Normalized Diluted EPS | -0.70 | -0.59 | -0.48 | -0.46 | -0.46 |
| Average Basic Shares Outstanding | 29.47M | 26.82M | 26.01M | 26.00M | 25.98M |
| Average Diluted Shares Outstanding | 29.86M | 26.82M | 26.01M | 26.00M | 26.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |